Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria
NCT00414336
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
150
Enrollment
NIH
Sponsor class
Conditions
Malaria
Interventions
DRUG:
AMA1-C1/Alhydrogel + CPG 7909 Vaccine
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)